Plamotamab is a monoclonal antibody commercialized by Xencor, with a leading Phase II program in Diffuse Large B-Cell Lymphoma. According to Globaldata, it is involved in 7 clinical trials, of which 3 are ongoing, and 4 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Plamotamab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Plamotamab is expected to reach an annual total of $81 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Plamotamab (XmAb-13676) is under development for the treatment of B cell malignancies such as Richter's transformation, relapsed/refractory diffuse large B-cell lymphoma, follicular lymphoma, Waldenstrom macroglobulinemia, relapsed and refractory Chronic Lymphocytic Leukemia, splenic marginal zone B-Cell Lymphoma extranodal marginal zone B-Cell Lymphoma, mantle cell lymphoma, Marginal Zone B-Cell Lymphoma, nodal marginal zone B-Cell Lymphoma and non B-cell chronic lymphocytic leukemia. It is administered intravenously. The drug candidate is a bi-specific monoclonal antibody that targets tumor antigen binding domain CD20 and cytotoxic T-cell CD3 binding domain. The drug candidate development is based on XmAb bi-specific antibody engineering technology.
Xencor is a clinical stage biopharmaceutical company that focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company product pipeline includes Vudalimab (PD1 x CTLA4), Plamotamab (CD20 x CD3), XmAb819 (ENPP3 x CD3), XmAb564 (IL-2-Fc) and XmAb104 (PD1 x ICOS). Xencor‘s Vudalimab is a bispecific antibody that simultaneously targets immune checkpoint receptors PD-1 and CTLA-4 and is designed to promote tumor-selective T-cell activation. Its Plamotamab is a tumor-targeted antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3). The company utilizes its proprietary XmAb technology platform to develop next generation antibody product candidates. . Xencor is headquartered in Monrovia, California, the US.
The company reported revenues of (US Dollars) US$275.1 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$122.7 million in FY2020. The operating profit of the company was US$43 million in FY2021, compared to an operating loss of US$76.8 million in FY2020. The net profit of the company was US$82.6 million in FY2021, compared to a net loss of US$69.3 million in FY2020. The company reported revenues of US$27.3 million for the third quarter ended September 2022, a decrease of 9.5% over the previous quarter.
For a complete picture of Plamotamab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.